Engineered Microbial Biosynthesis of Tryptamines From Anthranilate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing tryptamines, particularly substituted tryptamines, are inefficient and costly, and large-scale extraction from natural sources is challenging due to low concentrations and time-consuming cultivation processes, limiting access to these compounds for therapeutic uses.
Innovation Solution
Engineered microbial cells, such as Escherichia coli and Saccharomyces cerevisiae, are modified to express heterologous nucleic acid sequences encoding enzymes that convert anthranilate, indole, or tryptophan into tryptamines, allowing for biosynthetic production of substituted tryptamines in whole-cell biocatalysts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If tryptamines are extracted from natural sources, then the compounds can be obtained for therapeutic use, but the process is time-consuming and yields are low due to low concentrations in natural sources
Solution Approach 1:
The patent uses engineered microbial cells as intermediaries to convert readily available substrates (anthranilate, indole, or tryptophan) into tryptamines. These microbial factories act as mediators between simple chemical inputs and the desired tryptamine products, enabling efficient production without time-consuming natural cultivation.
Solution Approach 2:
The invention changes the production parameters by shifting from natural source extraction to biosynthetic production in engineered microbes. This parameter change includes using heterologous nucleic acid sequences to express enzymes that convert substrates to tryptamines, fundamentally altering the production methodology to achieve higher yields and faster turnaround.
2Ease of manufacture
If traditional organic synthesis methods are used to produce tryptamines, then compounds can be manufactured, but the processes are inefficient and costly
Solution Approach 1:
The patent replaces traditional organic synthesis mechanisms with biological catalysis. Instead of using chemical reagents and complex synthesis protocols, the invention employs engineered microbial cells with heterologous enzymes to catalyze the conversion of substrates to tryptamines, simplifying the manufacturing process and reducing costs.
Solution Approach 2:
The engineered microbial cells perform self-service by containing all necessary enzymatic pathways within the cell to convert substrates to tryptamines. The cells autonomously carry out the biosynthetic transformations without requiring external intervention or complex synthetic protocols, improving both efficiency and ease of manufacture.
3Quantity of substance
If large-scale extraction from natural sources is attempted, then more tryptamines can be obtained, but the process remains challenging due to low concentrations and cultivation constraints
Solution Approach 1:
The patent introduces engineered microbial cells as intermediaries that concentrate tryptamine production within the cell. This approach eliminates the need for complex extraction processes from natural sources, as the microbial factories directly produce high concentrations of tryptamines that can be easily harvested from culture media.
Solution Approach 2:
Instead of extracting tryptamines from natural sources, the invention inverts the approach by having engineered microbes synthesize tryptamines from simple substrates. This inversion simplifies the production process by replacing complex extraction with straightforward fermentation and harvesting operations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables high-yield, cost-effective production of tryptamines and their derivatives, facilitating access to novel compounds with therapeutic potential and avoiding the limitations of organic synthesis and natural extraction.
Implementation Method 1
the microbial cell containing therein one or more heterologous nucleic acid sequences encoding one or more enzymes involved in a biosynthesis pathway that converts an anthranilate to a tryptamine
Data Source
AI summary
Disclosed herein are prokaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamine and tryptamine derivatives. The microbes of the disclosure may be engineered to contain plasmids and stable gene integrations containing sufficient genetic information for conversion of an anthranilate or an indole to a tryptamine. The fermentative production of substituted tryptamines in a whole-cell biocatalyst may be useful for cost effective production of these compounds for therapeutic use.